Galderma’s relabotulinumtoxinA FDA setback shifts attention to manufacturing readiness
Discover why FDA manufacturing concerns have delayed Galderma’s relabotulinumtoxinA approval and what the company must resolve next.
Pharma & Biotech
Pharma & Biotech
Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada
Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.
Pharma & Biotech
Shantha Biologics wins high-stakes Novo Nordisk fill-finish mandate in Hyderabad
Read how Shantha Biologics’ Novo Nordisk cartridge fill-finish deal could reshape complex injectable manufacturing in India.
Pharma & Biotech
Contineum Therapeutics paper sharpens PIPE-791 case, but Phase 2 IPF data remain decisive
Discover why Contineum Therapeutics’ PIPE-791 paper strengthens the LPAR1 case while Phase 2 IPF data remain the decisive clinical test.
Pharma & Biotech
Lilly advances TRB-051 in lupus as TRexBio unveils the mechanism behind TRB-071
Explore how TRexBio’s TRB-071 CD30 agonist and Lilly-partnered TRB-051 could reshape tissue Treg drug development. Read the analysis.
Pharma & Biotech
Cellares enters FDA PreCheck as Cell Shuttle moves from automation promise to regulatory proof
Find out how Cellares’ FDA PreCheck selection could reshape automated cell therapy manufacturing while leaving product approval risks intact.
Pharma & Biotech
Orca Bio’s TREGZI enters the transplant market with a strong Phase 3 advantage
See how Orca Bio’s TREGZI FDA approval could reshape blood cancer transplants, reduce chronic GVHD and test cell therapy scale-up.
Pharma & Biotech
Fizurex advances toward human trials as Steel Therapeutics completes pivotal safety study
Discover how Steel Therapeutics’ Fizurex toxicology milestone could reshape anal fissure treatment as the program advances toward an FDA IND.
Pharma & Biotech
Why Biocytogen’s RenNano court win could shift the race for fully human VHH antibodies
Discover how Biocytogen’s RenNano court win could reshape VHH antibody licensing, platform risk and next-generation biologics development.
Pharma & Biotech
Can Neurogene’s NGN-401 restart developmental progress in patients with Rett syndrome?
Long-term Phase 1/2 data suggest that Neurogene’s NGN-401 gene therapy may produce continuing developmental gains across several functional domains in Rett syndrome. The small, uncontrolled dataset remains preliminary, however, leaving the larger Embolden registrational trial to determine whether those improvements are reproducible, clinically persuasive and sufficient for regulatory approval.